ASX - By Stock
|
NVA |
Re:
General Chat
|
|
pi065509
|
7.7K |
2.5M |
11 |
14/02/23 |
14/02/23 |
ASX - By Stock
|
7.7K
|
2.5M
|
11
|
|
ASX - By Stock
|
NVA |
Re:
General Chat
|
|
pi065509
|
7.7K |
2.5M |
5 |
14/02/23 |
14/02/23 |
ASX - By Stock
|
7.7K
|
2.5M
|
5
|
|
ASX - By Stock
|
NVA |
Re:
General Chat
|
|
pi065509
|
7.7K |
2.5M |
5 |
14/02/23 |
14/02/23 |
ASX - By Stock
|
7.7K
|
2.5M
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Canine Trial Update
|
|
pi065509
|
37 |
9.2K |
7 |
09/02/23 |
09/02/23 |
ASX - By Stock
|
37
|
9.2K
|
7
|
|
ASX - By Stock
|
NVA |
Re:
General Chat
|
|
pi065509
|
7.7K |
2.5M |
2 |
31/01/23 |
31/01/23 |
ASX - By Stock
|
7.7K
|
2.5M
|
2
|
|
ASX - By Stock
|
ASR |
Re:
Ann: Asra Completes Strategic Ownership of the Tarmoola Station
|
|
pi065509
|
30 |
12K |
1 |
25/01/23 |
25/01/23 |
ASX - By Stock
|
30
|
12K
|
1
|
|
ASX - By Stock
|
ASR |
Re:
Ann: Asra Completes Strategic Ownership of the Tarmoola Station
|
|
pi065509
|
30 |
12K |
2 |
25/01/23 |
25/01/23 |
ASX - By Stock
|
30
|
12K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Progresses to Elevated Doses in MND Patients
|
|
pi065509
|
79 |
18K |
4 |
24/01/23 |
24/01/23 |
ASX - By Stock
|
79
|
18K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Progresses to Elevated Doses in MND Patients
|
|
pi065509
|
79 |
18K |
4 |
24/01/23 |
24/01/23 |
ASX - By Stock
|
79
|
18K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Progresses to Elevated Doses in MND Patients
|
|
pi065509
|
79 |
18K |
3 |
24/01/23 |
24/01/23 |
ASX - By Stock
|
79
|
18K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Bella's Monepantel Trial
|
|
pi065509
|
127 |
28K |
14 |
19/01/23 |
19/01/23 |
ASX - By Stock
|
127
|
28K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Top 100 PAA Option Holders as at 29/12/2020 with only one variation.variations.
|
|
pi065509
|
64 |
18K |
5 |
10/01/23 |
10/01/23 |
ASX - By Stock
|
64
|
18K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Trial Successfully Completes First Patient Cohort
|
|
pi065509
|
164 |
40K |
2 |
09/01/23 |
09/01/23 |
ASX - By Stock
|
164
|
40K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Top 100 PAA Option Holders as at 29/12/2020 with only one variation.variations.
|
|
pi065509
|
64 |
18K |
6 |
02/01/23 |
02/01/23 |
ASX - By Stock
|
64
|
18K
|
6
|
|
ASX - By Stock
|
NVA |
Re:
General Chat
|
|
pi065509
|
7.7K |
2.5M |
3 |
29/12/22 |
29/12/22 |
ASX - By Stock
|
7.7K
|
2.5M
|
3
|
|
ASX - By Stock
|
RGT |
Re:
Ann: US$1,000,000 ArtemiC order delivered to US partner, AMC
|
|
pi065509
|
16 |
4.6K |
4 |
06/12/22 |
06/12/22 |
ASX - By Stock
|
16
|
4.6K
|
4
|
|
ASX - By Stock
|
NVA |
Re:
Ann: Results of Meeting
|
|
pi065509
|
236 |
69K |
6 |
02/12/22 |
02/12/22 |
ASX - By Stock
|
236
|
69K
|
6
|
|
ASX - By Stock
|
NVA |
Re:
Ann: Results of Meeting
|
|
pi065509
|
236 |
69K |
13 |
02/12/22 |
02/12/22 |
ASX - By Stock
|
236
|
69K
|
13
|
|
ASX - By Stock
|
PAA Biotech |
Re:
2023 , MND, K9 Cancer Commercial Deal , Covid , Human Cancer, OHD
|
|
pi065509
|
153 |
41K |
3 |
01/12/22 |
01/12/22 |
ASX - By Stock
|
153
|
41K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III
|
|
pi065509
|
1.4K |
377K |
2 |
24/11/22 |
24/11/22 |
ASX - By Stock
|
1.4K
|
377K
|
2
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III
|
|
pi065509
|
1.4K |
377K |
6 |
22/11/22 |
22/11/22 |
ASX - By Stock
|
1.4K
|
377K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
PAA Post AGM ,, 2022 Highlights
|
|
pi065509
|
207 |
48K |
9 |
13/11/22 |
13/11/22 |
ASX - By Stock
|
207
|
48K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
PAA Post AGM ,, 2022 Highlights
|
|
pi065509
|
207 |
48K |
6 |
13/11/22 |
13/11/22 |
ASX - By Stock
|
207
|
48K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
PAA Post AGM ,, 2022 Highlights
|
|
pi065509
|
207 |
48K |
7 |
12/11/22 |
12/11/22 |
ASX - By Stock
|
207
|
48K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: AGM Presentation
|
|
pi065509
|
54 |
9.8K |
3 |
10/11/22 |
10/11/22 |
ASX - By Stock
|
54
|
9.8K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor Webinar
|
|
pi065509
|
42 |
7.9K |
0 |
05/11/22 |
05/11/22 |
ASX - By Stock
|
42
|
7.9K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Ann: DNDi contract extension for PharmAust subsidiary Epichem
|
|
pi065509
|
14 |
3.8K |
10 |
03/11/22 |
03/11/22 |
ASX - By Stock
|
14
|
3.8K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor Webinar
|
|
pi065509
|
42 |
7.9K |
8 |
01/11/22 |
01/11/22 |
ASX - By Stock
|
42
|
7.9K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C and Quarterly Update
|
|
pi065509
|
41 |
9.6K |
13 |
31/10/22 |
31/10/22 |
ASX - By Stock
|
41
|
9.6K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: First Patient Dosed in MND Phase 1/2 Trial
|
|
pi065509
|
171 |
43K |
3 |
27/10/22 |
27/10/22 |
ASX - By Stock
|
171
|
43K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Update on PharmAust Canine Cancer Trials
|
|
pi065509
|
216 |
48K |
5 |
20/10/22 |
20/10/22 |
ASX - By Stock
|
216
|
48K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Update on PharmAust Canine Cancer Trials
|
|
pi065509
|
216 |
48K |
15 |
19/10/22 |
19/10/22 |
ASX - By Stock
|
216
|
48K
|
15
|
|
ASX - By Stock
|
NVA |
Re:
Ann: High Grade Gold Intercepts Continue for Nova at RPM
|
|
pi065509
|
63 |
29K |
13 |
15/10/22 |
15/10/22 |
ASX - By Stock
|
63
|
29K
|
13
|
|
ASX - By Stock
|
NVA |
Re:
Ann: RPM Gold Deposit Operational Update
|
|
pi065509
|
369 |
134K |
2 |
23/09/22 |
23/09/22 |
ASX - By Stock
|
369
|
134K
|
2
|
|
ASX - By Stock
|
NVA |
Re:
Ann: Annual Report to shareholders - 30 June 2022
|
|
pi065509
|
20 |
6.9K |
9 |
21/09/22 |
21/09/22 |
ASX - By Stock
|
20
|
6.9K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: First Patient in US Canine Cancer Trials Begins Treatment
|
|
pi065509
|
98 |
18K |
3 |
07/09/22 |
07/09/22 |
ASX - By Stock
|
98
|
18K
|
3
|
|
ASX - By Stock
|
NVA |
Re:
Ann: Drilling Now Commenced at Cathedral within the Korbel Valley
|
|
pi065509
|
63 |
21K |
6 |
30/08/22 |
30/08/22 |
ASX - By Stock
|
63
|
21K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust The Good News , Progress and Moving Forward
|
|
pi065509
|
64 |
16K |
4 |
11/08/22 |
11/08/22 |
ASX - By Stock
|
64
|
16K
|
4
|
|
ASX - By Stock
|
NVA |
Re:
Ann: Exceptional High-Grade Gold Continues at RPM North
|
|
pi065509
|
123 |
51K |
0 |
08/08/22 |
08/08/22 |
ASX - By Stock
|
123
|
51K
|
0
|
|
ASX - By Stock
|
NVA |
Re:
Ann: Exceptional High-Grade Gold Continues at RPM North
|
|
pi065509
|
123 |
51K |
5 |
08/08/22 |
08/08/22 |
ASX - By Stock
|
123
|
51K
|
5
|
|
ASX - By Stock
|
NVA |
Re:
Ann: Trading Halt
|
|
pi065509
|
152 |
66K |
1 |
08/08/22 |
08/08/22 |
ASX - By Stock
|
152
|
66K
|
1
|
|
ASX - By Stock
|
NVA |
Re:
Ann: Trading Halt
|
|
pi065509
|
152 |
66K |
3 |
06/08/22 |
06/08/22 |
ASX - By Stock
|
152
|
66K
|
3
|
|
ASX - By Stock
|
NVA |
Re:
Ann: Trading Halt
|
|
pi065509
|
152 |
66K |
18 |
05/08/22 |
05/08/22 |
ASX - By Stock
|
152
|
66K
|
18
|
|
ASX - By Stock
|
PAA |
Re:
Latest JP Equity Research Report - July 2022
|
|
pi065509
|
36 |
8.9K |
9 |
27/07/22 |
27/07/22 |
ASX - By Stock
|
36
|
8.9K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust The Good News , Progress and Moving Forward
|
|
pi065509
|
64 |
16K |
9 |
26/07/22 |
26/07/22 |
ASX - By Stock
|
64
|
16K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C and Quarterly Update
|
|
pi065509
|
44 |
10K |
8 |
20/07/22 |
20/07/22 |
ASX - By Stock
|
44
|
10K
|
8
|
|
ASX - By Stock
|
NVA |
Re:
Ann: RPM Gold Deposit Operational Update
|
|
pi065509
|
369 |
134K |
1 |
08/07/22 |
08/07/22 |
ASX - By Stock
|
369
|
134K
|
1
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III
|
|
pi065509
|
1.4K |
377K |
2 |
08/07/22 |
08/07/22 |
ASX - By Stock
|
1.4K
|
377K
|
2
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III
|
|
pi065509
|
1.4K |
377K |
7 |
08/07/22 |
08/07/22 |
ASX - By Stock
|
1.4K
|
377K
|
7
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III
|
|
pi065509
|
1.4K |
377K |
2 |
08/07/22 |
08/07/22 |
ASX - By Stock
|
1.4K
|
377K
|
2
|
|